Nataly Hastings

CEO, Cellestial Health

Dr Nat Hastings has background in clinical research and bioengineering at the University of Cambridge, focussing on Parkinson's disease modification and brain cell network communication. She led the relevant academic project since 2018 and managed the Cellestial Health spin-out process in 2023. As the CEO of Cellestial Health, her goal is to transform academic insights into a tangible patient benefit. 

Abigail Martin

Co-Founder & CCO, ImmuONE

Dr Abigail Martin is a scientist turned entrepreneur in biotech, with a passion for applying research to the commercial world. She cofounded university spin out ImmuONE in 2019 with the aim to engage with inhalation and allergy industries, advocating for standardised in vitro technologies. With early on support from Innovate UK followed by recent seed investment of +£2M, she continues to lead the revenue making venture from start up to scale up. As CEO, she is passionate about supporting alternative methods to animal testing, empowering her colleagues and navigating ImmuONE on its growth trajectory. To date the company has launched multiple human-lung and immune in-vitro products, offering standard testing and advanced assays to assist clients in bringing products to market. 

Jonathan Kwok

Co-Founder & CEO, Infinitopes

Dr. Kwok is a clinician scientist and Cancer Research UK (CRUK) cancer vaccines fellow at Oxford University. He enjoys more than two decades of professional experience across the fields of oncology, vaccinology, clinical trials, strategy consulting and investment banking. He co-founded Infinitopes Precision Immunomics in 2021, bringing together world leading experts in antigen discovery, T-cell immunology, computation/ML, vaccine design/molecular biology, biomanufacturing and medicines regulation. His mission is to develop accessible, high efficiency vaccines to prevent cancer metastases.

Stasa Stankovic

Co-Founder, Ovartix

Dr Stasa Stankovic is a world leading scientist in reproductive medicine, holding an MPhil and PhD in Reproductive Genomics from the University of Cambridge. She focuses on deciphering genetic architecture of reproductive ageing, fertility and menopause, and their link to other health conditions and longevity in women. Commercialising her PhD, today she is a co-founder and CEO of OvartiX, a women’s health drug discovery company aiming to develop next-generation therapeutics for reproductive disorders like infertility, polycystic ovarian syndrome, menopause etc. She also works as a strategy consultant for AstraZeneca, where she is defining and growing corporate-wide strategy around application of human omics, AI and ML for drug discovery, and Cercle AI, an AI women’s health startup.

Based on her work, she was awarded ‘McKinsey&Company Next Generation Women Leader’ for 2020, the best young investigator under the age of 40 by the International Menopause Society ('Robert Greenblatt Award'), one of ten best UK young scientists in the biomedical sector by the UK Government ‘STEM for Britain’, one of top 100 women in tech in the UK by Barclays, One of top 200 trailblazing women in women’s health and femtech by Covington and Women of Wearables, and she is considered as one of 11 scientists with the highest impact on innovations in menopause and reproductive health by Forbes.

Inga Deakin

Partner, Molten VC

Inga brings hands-on investment experience in life sciences and digital health, working with ventures spun out of leading UK universities. Her career has also included time in the US, where she gained international industry and healthcare expertise as Chief of Staff at a commercial-stage genetic molecular diagnostics company, and as Entrepreneur in Residence at Duke University. 

Her scientific foundation includes a DPhil and MSc in Neuroscience from the University of Oxford, complemented by a BA from the University of Cambridge. This blend of academic rigor and industry insight fuels her enthusiasm for supporting innovators who are advancing the future of healthcare.